Internal Medicine, Crozer Chester Medical Center, 1 Medical Center Blvd, Upland, PA, 19013, USA.
Hematology/Oncology Department, Alliance Cancer Specialist, Crozer Chester Medical Center, Upland, USA.
Med Oncol. 2021 Apr 23;38(6):61. doi: 10.1007/s12032-021-01507-9.
Pancreatic cancer, being one of the most fatal cancers, is the 7th leading cause of death globally. Cancer that is resistant to current treatment proves that there is a need for personalized and targeted therapy, based on the tumor and genomic markers. Pembrolizumab and Larotrectinib are examples of current medications used as targeted therapy in pancreatic cancer. Pancreatic cancer has many different molecular subgroups, providing the opportunity for the development of new drugs that can target these groups. Poly (ADP-Ribose) polymerase inhibitors (PARPi) are a group of drugs inhibiting PARP to decrease the stability of the cancer cells. Currently, PARPi are mostly used in ovarian and breast cancer. There are multiple studies that have shown positive effects of PARPi in decreasing the tumor burden in advanced pancreatic cancer. PARPi are the future of pancreatic cancer management, and hence it is important to understand their mechanism, resistance pathways, and their application in the real world.
胰腺癌是最致命的癌症之一，是全球第七大致死原因。对当前治疗方法有抗药性的癌症表明，需要根据肿瘤和基因组标记物进行个性化和靶向治疗。派姆单抗（Pembrolizumab）和拉罗替尼（Larotrectinib）是目前用于胰腺癌靶向治疗的药物示例。胰腺癌有许多不同的分子亚群，为开发可以针对这些群体的新药提供了机会。聚（ADP-核糖）聚合酶抑制剂（PARPi）是一组抑制 PARP 以降低癌细胞稳定性的药物。目前，PARPi 主要用于卵巢癌和乳腺癌。多项研究表明，PARPi 可有效降低晚期胰腺癌的肿瘤负担。PARPi 是胰腺癌管理的未来，因此了解其作用机制、耐药途径以及在现实世界中的应用非常重要。
